Allergy Therapeutics plc (LON:AGY – Get Free Report) shares fell 6.7% during trading on Monday. The company traded as low as GBX 3.43 and last traded at GBX 3.50. Approximately 210,300 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 332,814 shares. The stock had previously closed at GBX 3.75.
Allergy Therapeutics Price Performance
The company’s fifty day moving average is GBX 4.78 and its two-hundred day moving average is GBX 8.01. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The firm has a market capitalization of £82.32 million, a price-to-earnings ratio of -1.34, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
